Chronic kidney disease and menopausal health: An EMAS clinical guide.
Options
BORIS DOI
Publisher DOI
PubMed ID
39609235
Description
Unlabelled
Kidney diseases are related to the aging process. Ovarian senescence and the loss of estrogen's renoprotective effects are directly associated with a decline in renal function and indirectly with an accumulation of cardiometabolic risk factors. The latter can predispose to the development of chronic kidney disease (CKD). Conversely, CKD diagnosed during reproductive life adversely affects ovarian function.Aim
To set out an individualized approach to menopause management in women with CKD.Materials And Methods
Literature review and consensus of expert opinion.Summary Recommendations
Menopause hormone therapy can be given to women with CKD. The regimen should be selected on the basis of patient preference and the individual's cardiovascular risk. The dose of hormonal and non-hormonal preparations should be adjusted in accordance with the patient's creatinine clearance. The management of a postmenopausal woman with CKD should focus on lifestyle advice as well as regular monitoring of the main cardiovascular risk factors and evaluation of bone mineral density. Tailored multidisciplinary advice should be given to women with comorbidities such as diabetes, dyslipidemia, and hypertension. Management of osteoporosis should be based on the severity of the CKD.
Kidney diseases are related to the aging process. Ovarian senescence and the loss of estrogen's renoprotective effects are directly associated with a decline in renal function and indirectly with an accumulation of cardiometabolic risk factors. The latter can predispose to the development of chronic kidney disease (CKD). Conversely, CKD diagnosed during reproductive life adversely affects ovarian function.Aim
To set out an individualized approach to menopause management in women with CKD.Materials And Methods
Literature review and consensus of expert opinion.Summary Recommendations
Menopause hormone therapy can be given to women with CKD. The regimen should be selected on the basis of patient preference and the individual's cardiovascular risk. The dose of hormonal and non-hormonal preparations should be adjusted in accordance with the patient's creatinine clearance. The management of a postmenopausal woman with CKD should focus on lifestyle advice as well as regular monitoring of the main cardiovascular risk factors and evaluation of bone mineral density. Tailored multidisciplinary advice should be given to women with comorbidities such as diabetes, dyslipidemia, and hypertension. Management of osteoporosis should be based on the severity of the CKD.
Date of Publication
2025-01
Publication Type
Article
Keyword(s)
Chronic kidney disease
•
Menopausal hormone therapy
•
Menopause
Language(s)
en
Contributor(s)
Cevik, E Cansu | |
Erel, C Tamer | |
Ozcivit Erkan, Ipek Betul | |
Sarafidis, Pantelis | |
Armeni, Eleni | |
Fistonić, Ivan | |
Hillard, Timothy | |
Hirschberg, Angelica Lindén | |
Meczekalski, Blazej | |
Mendoza, Nicolás | |
Mueck, Alfred O | |
Simoncini, Tommaso | |
van Dijken, Dorenda | |
Rees, Margaret | |
Lambrinoudaki, Irene |
Additional Credits
Series
Maturitas: An international journal of midlife health and beyond
Publisher
Elsevier
ISSN
1873-4111
0378-5122
Access(Rights)
restricted